

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

GRANT OF OPTIONS

The Board announces that on 25 April 2017, 27,550,000 Options were granted at an exercise price of HK\$3.512 per Share, subject to acceptance of the grantees, under the Share Option Scheme. None of the grantees of the Options is a Director, chief executive or substantial shareholder (as defined in the Listing Rules) of the Company, or an associate (as defined in the Listing Rules) of any of them.

This announcement is made pursuant to Rule 17.06A of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The board (the “**Board**”) of directors (the “**Directors**”) of Genscript Biotech Corporation (the “**Company**”) announces that on 25 April 2017 (the “**Date of Grant**”), 27,550,000 share options (the “**Option(s)**”) to subscribe for an aggregate of 27,550,000 ordinary shares of US\$0.001 each of the Company (the “**Share(s)**”) were granted, subject to acceptance of the grantees, under the Company’s post-IPO share option scheme adopted on 7 December 2015 (the “**Share Option Scheme**”). The details of the Options granted are set out below:

Date of Grant:	25 April 2017
Exercise price of Options granted:	Each Option shall entitle the holder of the Option to subscribe for one Share upon exercise of such Option at an exercise price of HK\$3.512 per Share, being the highest of (i) the closing price of the Shares on the Date of Grant, (ii) the average closing price of the Shares as quoted on the Stock Exchange for the five business days immediately preceding the Date of Grant, and (iii) the nominal value of a Share on the Date of Grant
Number of Options granted:	27,550,000 Options
Closing price of the Shares on the Date of Grant:	HK\$3.45 per Share
Average closing price per Share for the five business days immediately preceding the Date of Grant:	HK\$3.512 per Share
Validity period of the Options:	25 April 2017 to 24 April 2027, both dates inclusive

None of the grantees of the Options is a Director, chief executive or substantial shareholder (as defined in the Listing Rules) of the Company, or an associate (as defined in the Listing Rules) of any of them.

By order of the Board
Genscript Biotech Corporation
Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 25 April 2017

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan, Mr. Huang Zuie-Chin and Mr. Pan Yuexin; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Ms. Zhang Min.

* *For identification purposes only*